About Integra LifeSciences Holdings Corporation
https://www.integralife.comIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
CEO
Mojdeh Poul
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-01-04 | Forward | 2:1 |
| 2015-07-01 | Forward | 553:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 159
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Argus Research
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wells Fargo
Equal Weight
Truist Securities
Hold
JP Morgan
Underweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:11.25M
Value:$141.01M
BLACKROCK, INC.
Shares:10.23M
Value:$128.17M
RUBRIC CAPITAL MANAGEMENT LP
Shares:7.65M
Value:$95.9M
Summary
Showing Top 3 of 304
About Integra LifeSciences Holdings Corporation
https://www.integralife.comIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $402.06M ▼ | $185.82M ▼ | $-5.4M ▲ | -1.34% ▲ | $-0.07 ▲ | $54.06M ▲ |
| Q2-2025 | $415.61M ▲ | $722.01M ▲ | $-484.07M ▼ | -116.47% ▼ | $-6.33 ▼ | $-472.22M ▼ |
| Q1-2025 | $382.65M ▼ | $209.93M ▼ | $-25.29M ▼ | -6.61% ▼ | $-0.33 ▼ | $25.97M ▼ |
| Q4-2024 | $442.65M ▲ | $213.44M ▲ | $19.43M ▲ | 4.39% ▲ | $0.25 ▲ | $79.11M ▲ |
| Q3-2024 | $380.83M | $208.39M | $-10.7M | -2.81% | $-0.14 | $34.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $267.88M ▲ | $3.65B ▼ | $2.61B ▼ | $1.04B ▼ |
| Q2-2025 | $253.61M ▼ | $3.67B ▼ | $2.63B ▲ | $1.04B ▼ |
| Q1-2025 | $273.3M ▼ | $4.05B ▲ | $2.53B ▲ | $1.52B ▼ |
| Q4-2024 | $273.57M ▼ | $4.04B ▼ | $2.49B ▼ | $1.55B ▲ |
| Q3-2024 | $277.6M | $4.07B | $2.54B | $1.52B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.4M ▲ | $40.91M ▲ | $-15.59M ▲ | $-10.24M ▲ | $14.27M ▲ | $25.75M ▲ |
| Q2-2025 | $-484.07M ▼ | $8.92M ▲ | $-21.65M ▲ | $-21.14M ▼ | $-21.19M ▼ | $-11.23M ▲ |
| Q1-2025 | $-25.29M ▼ | $-11.26M ▼ | $-35.92M ▼ | $35.38M ▲ | $-7.27M ▼ | $-40.18M ▼ |
| Q4-2024 | $19.43M ▲ | $50.74M ▲ | $-4.25M ▲ | $-7.15M ▲ | $31.22M ▲ | $11.19M ▲ |
| Q3-2024 | $-10.7M | $22.48M | $-10.4M | $-19.91M | $-79K | $-7.16M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Codman Specialty Surgical | $310.00M ▲ | $280.00M ▼ | $300.00M ▲ | $290.00M ▼ |
 Tissue Technologies | $130.00M ▲ | $100.00M ▼ | $110.00M ▲ | $110.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Asia Pacific | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ | $50.00M ▲ |
 Europe | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 Rest Of The World | $0 ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 UNITED STATES | $340.00M ▲ | $300.00M ▼ | $280.00M ▼ | $310.00M ▲ |
CEO
Mojdeh Poul
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-01-04 | Forward | 2:1 |
| 2015-07-01 | Forward | 553:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 159
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Argus Research
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wells Fargo
Equal Weight
Truist Securities
Hold
JP Morgan
Underweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:11.25M
Value:$141.01M
BLACKROCK, INC.
Shares:10.23M
Value:$128.17M
RUBRIC CAPITAL MANAGEMENT LP
Shares:7.65M
Value:$95.9M
Summary
Showing Top 3 of 304